Patents by Inventor Aubin PENNA

Aubin PENNA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides and uses thereof for reducing CD95-mediated cell motility
    Patent number: 10556941
    Abstract: The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: February 11, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE BORDEAUX, UNIVERSITÉ DE RENNES, ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE (EHESP), UNIVERSITÉ DES ANTILLES ET DE LA GUYANE, INSTITUT BERGONIÉ, UNIVERSITY OF NOTTINGHAM
    Inventors: Patrick Legembre, Pierre Vacher, Doriane Sanseau, Aubin Penna, Robin Flynn
  • POLYPEPTIDES AND USES THEREOF FOR REDUCING CD95-MEDIATED CELL MOTILITY
    Publication number: 20190085050
    Abstract: The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility.
    Type: Application
    Filed: October 10, 2018
    Publication date: March 21, 2019
    Inventors: Patrick LEGEMBRE, Pierre VACHER, Doriane SANSEAU, Aubin PENNA, Robin FLYNN
  • Polypeptides and uses thereof for reducing CD95-mediated cell motility
    Patent number: 10189887
    Abstract: The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: January 29, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE BORDEAUX, UNIVERSITE DE RENNES, ECOLE DES HAUTES ETUDES EN SANTE PUBLIQUE (EHESP), UNIVERSITE DES ANTILLES ET DE LA GUYANE, INSTITUTE BERGONIE, UNIVERSITY OF NOTTINGHAM
    Inventors: Patrick Legembre, Pierre Vacher, Doriane Sanseau, Aubin Penna, Robin Flynn
  • POLYPEPTIDES AND USES THEREOF FOR REDUCING CD95-MEDIATED CELL MOTILITY
    Publication number: 20170044234
    Abstract: The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.
    Type: Application
    Filed: April 16, 2015
    Publication date: February 16, 2017
    Applicant: Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Patrick LEGEMBRE, Pierre VACHER, Doriane SANSEAU, Aubin PENNA, Robin FLYNN